Pharmacopeia Confirms Blockade Of Angiotensin II Response With First In Class PS433540 (DARA)
Pharmacopeia (Nasdaq: PCOP), an innovator in the discovery and development of novel small molecule therapeutics, announced confirmation of the ability of PS433540 (DARA) to block the angiotensin II (AII) response in a Phase 1 trial in healthy volunteers. Numerous similar studies with other agents that block the renin angiotensin system support that this result is a strong indication that PS433540 can be expected to lower blood pressure in hypertensive patients.
